GlassScriptPhysician profile
Charles Minn
NPI 1508119736
$67,165.02
in general payments reported to CMS, 2019-2025
24 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $7,956 · 2021: $2,923 · 2022: $26K · 2023: $17K · 2024: $446 · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Travel and Lodging: $3,381 · Food and Beverage: $2,348 · Consulting Fee: $229 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,905.00 |
| Travel and Lodging | $3,380.63 |
| Food and Beverage | $2,348.45 |
| Consulting Fee | $229.29 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Btg International INC. | $39,125.75 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $14,263.44 | 2020-2025 | Lokelma, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $9,298.97 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $1,441.58 | 2019-2020 | |
| Vifor Pharma, INC. | $750.24 | 2019-2021 | |
| Novo Nordisk INC | $629.31 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Outset Medical INC | $431.55 | 2024-2025 | |
| Glaxosmithkline, LLC. | $208.02 | 2023 | Benlysta, Jesduvroq |
| Otsuka America Pharmaceutical, INC. | $122.40 | 2019 | |
| Aurinia Pharma U.S., INC. | $121.94 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $102.22 | 2024-2025 | Austedo Xr, Austedo Xr |
| Medtronic, INC. | $97.69 | 2021 | |
| Amgen INC. | $96.56 | 2019-2025 | Krystexxa |
| Horizon Therapeutics Plc | $91.10 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.52 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $66.56 | 2019-2023 | Jynarque |
| Bard Peripheral Vascular, INC. | $66.43 | 2021 | |
| Alnylam Pharmaceuticals INC. | $33.74 | 2025 | Amvuttra |
| Fresenius USA Marketing, INC. | $33.09 | 2019 | |
| Ani Pharmaceuticals, INC. | $29.41 | 2025 | Purified Cortrophin Gel |
| Lundbeck LLC | $28.20 | 2025 | Rexulti |
| Lilly USA, LLC | $18.46 | 2025 | Kisunla |
| Scpharmaceuticals INC. | $17.53 | 2023 | |
| Akebia Therapeutics INC | $16.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Minn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.